Revance Therapeutics, Inc. (NASDAQ:RVNC) Receives $9.66 Average Price Target from Analysts

Revance Therapeutics, Inc. (NASDAQ:RVNC - Get Free Report) has been assigned an average rating of "Hold" from the nine ratings firms that are presently covering the company, Marketbeat Ratings reports. Eight equities research analysts have rated the stock with a hold rating and one has issued a buy rating on the company. The average 12 month target price among brokers that have issued a report on the stock in the last year is $9.66.

Several equities research analysts recently issued reports on the company. Barclays reiterated an "equal weight" rating and issued a $7.00 price objective (down previously from $10.00) on shares of Revance Therapeutics in a report on Friday, September 13th. Stifel Nicolaus reduced their price target on shares of Revance Therapeutics from $24.00 to $20.00 and set a "buy" rating on the stock in a research report on Friday, August 9th. Piper Sandler lowered shares of Revance Therapeutics from a "strong-buy" rating to a "hold" rating in a research note on Monday, August 12th. StockNews.com started coverage on shares of Revance Therapeutics in a research note on Wednesday. They set a "hold" rating on the stock. Finally, HC Wainwright reissued a "neutral" rating and issued a $6.60 price target on shares of Revance Therapeutics in a research report on Friday, November 8th.

Revance Therapeutics Stock Performance

Shares of Revance Therapeutics stock traded down $0.12 on Friday, reaching $3.82. The company had a trading volume of 1,150,762 shares, compared to its average volume of 2,617,773. The firm has a market cap of $400.72 million, a PE ratio of -1.98 and a beta of 0.81. The firm's 50 day moving average price is $4.77 and its two-hundred day moving average price is $4.46. Revance Therapeutics has a 52-week low of $2.30 and a 52-week high of $9.74.

Revance Therapeutics (NASDAQ:RVNC - Get Free Report) last announced its earnings results on Thursday, November 7th. The biopharmaceutical company reported ($0.37) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.35) by ($0.02). The business had revenue of $59.88 million during the quarter, compared to the consensus estimate of $67.73 million. As a group, sell-side analysts predict that Revance Therapeutics will post -1.54 EPS for the current year.

Institutional Investors Weigh In On Revance Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of RVNC. Certuity LLC purchased a new position in Revance Therapeutics in the second quarter valued at $26,000. FORA Capital LLC acquired a new position in shares of Revance Therapeutics during the 3rd quarter worth about $54,000. Creative Planning purchased a new position in shares of Revance Therapeutics in the 3rd quarter valued at about $56,000. Vanguard Personalized Indexing Management LLC acquired a new stake in shares of Revance Therapeutics during the 2nd quarter worth about $33,000. Finally, Accredited Investors Inc. purchased a new stake in Revance Therapeutics during the third quarter worth approximately $67,000. 97.70% of the stock is currently owned by institutional investors and hedge funds.

About Revance Therapeutics

Revance Therapeutics, Inc, a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar lines and cervical dystonia; has completed phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis.